 cisplatin continuous-infus intermediate-dos methotrex treatment unresect non-smal cell carcinoma lung patient unresect non-smal cell carcinoma lung nsccl cisplatin day daili bolu inject continu infus day intermediate-dos methotrex day cycl pfm complet partial respons overal respons rate signific differ respons rate histolog subtyp extent diseas unresect versu metastat median durat respons month median surviv patient month patient unresect diseas present resect chemotherapi disease-fre month toxic modest oral mucos major advers effect clinic import neutropenia uncommon pfm activ regimen nsccl studi neoadjuv set